Prevalidation of the rat CFU-GM assay for in vitro toxicology applications

Alternatives to Laboratory Animals

Volumn 38, Issue 2, 2010, Pages 105-117

  Pessina, Augusto ^a   Bonomi, Arianna ^a   Cavicchini, Loredana ^a   Albella, Beatriz ^b   Cerrato, Laura ^b   Parent Massin, Dominique ^c   Sibiril, Yann ^c   Parchment, Ralph ^d   Behrsing, Holger ^d   Verderio, Paolo ^e   Pizzamiglio, Sara ^e   Giangreco, Manuela ^e   Baglio, Carolina ^a   Coccè, Valentine ^a   Sisto, Francesca ^a   Gribaldo, Laura ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b CIEMAT   (Spain)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Nazionale dei Tumori   (Italy)

^f JOINT RESEARCH CENTRE   (Italy)

Author keywords

In vitro toxicity; Myelotoxicity; Prevalidation; Rat CFU GM

Indexed keywords

DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; INDOMETACIN; METHOTREXATE; PACLITAXEL;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; APLASTIC ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELL ISOLATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERSENSITIVITY REACTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ULCER; MEGAKARYOCYTE; MOUSE; MOUTH ULCER; MUCOSA INFLAMMATION; MYELOID PROGENITOR CELL; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RAT; THROMBOCYTOPENIA; TISSUE INJURY; TOXICITY TESTING; VALIDATION STUDY;

ANIMALIA; RATTUS;

EID: 77953731933     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119291003800212     Document Type: Article

References (32)

1. Lewis, I.D., Rawling, T., Dyson, P.G., Haylock, D.N., Juttner, D.N. & To, L.B. (1996). Standardization of the CFU-GM assay using hematopoietic growth factors. Journal of Hematotherapy 5, 625-630.
2. Gribaldo, L., Bueren, J., Deldar, A., Okland, P., Meredith, C., Moneta, D., Mosesso, P., Parchment, R., Parent-Massin, D., Pessina, A., San Roman, J. & Schoeters, G. (1996). The use of in vitro systems for evaluating haematotoxicity. The report and recommendations of ECVAM Workshop 14. ATLA 24, 211-231.
3. Metcalf, D. (1984). The basic biology of hematopoiesis. In The Haematopoietic Colony Stimulating Factors (ed. D. Metcalf), pp 1-26. Amsterdam, The Netherlands: Elsevier.
4. Pessina, A., Parent-Massin, D., Albella, B., Van Den Heuvel, R., Casati, S., Croera, C., Malerba, I., Sibiril, Y., Gomez, S., de Smedt, A. & Gribaldo, L. (2009). Application of human CFU-MK assay to predict potential thrombocytotoxicity of drugs. Toxicology in Vitro 23, 194-200.
5. Parchment, R.E., Huang, M. & Erickson-Miller, C.L. (1993). Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicologic Pathology 21, 241-250.
6. Pessina, A. (1998). The Granulocyte Macrophage Colony-Forming Unit Assay. In Animal Cell Culture Techniques (ed. M. Clynes), pp. 217-230. Berlin-Heidelberg, Germany: Springer-Verlag.
7. Parchment, R.E. (1998). Alternative testing systems for evaluating non-carcinogenic, hematologic toxicity. Environmental Health Perspectives 106, 541-557.
8. Parchment, R.E., Gordon, M., Grieshaber, C.K., Sessa, C., Volpe, D. & Ghielmini, M. (1998). Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Annals of Oncology 9, 357-364. (Pubitemid 28273026)
9. Pessina, A., Albella, B., Bueren, J., Brantom, P., Casati, S., Gribaldo, L., Croera, C., Gagliardi, G., Foti, P., Parchment, R., Parent-Massin, D., Sibiril, Y., Schoeters, G. & Van Den Heuvel, R. (2001). Prevalidation of a model for predicting acute neutropenia by Colony Forming Unit-Granulocyte/ Macrophage (CFU-GM) assay. Toxicology in Vitro 15, 729-740.
10. Pessina, A., Albella, B., Bayo, M., Bueren, J., Brantom, P., Casati, S., Croera, C., Gagliardi, G., Foti, P., Parchment, R., Parent-Massin, D., Schoeters, G., Sibiril, Y., Van Den Heuvel, R., Gribaldo, L. (2003). Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicological Sciences 75, 355-367.
11. Pessina, A., Bonomi, A., Baglio, C., Cavicchini, L. & Gribaldo, L. (2009). Refinement and optimisation of the rat CFU-GM assay to incorporate the use of cryopreserved bone-marrow cells for in vitro toxicology applications. ATLA 37, 417-425.
12. Curren, R.D., Southee, J.A., Spielmann, H., Liebsch, M., Fentem, J.H. & Balls, M. (1995). The role of prevalidation and validation in the development, validation and acceptance of alternative methods. ATLA 23, 211-217.
13. Balls, M., Blaauboer, B.J., Fentem, J.H., Bruner, L., Combes, R.D., Ekwall, B., Fielder, R.J., Guillouzo, A., Lewis, R.W., Lovell, D.P., Reinhardt, C.A., Repetto, G., Sladowski, D., Spielmann, H. & Zucco, F. (1995). Pratical aspects of the validation of toxicity test procedures. The report and recommendations of ECVAM Workshop 5. ATLA 23, 129-147.
14. Balls, M. & Karcher, W. (1995). The validation of alternative test methods. ATLA 23, 884-886.
15. Pessina, A., Eletti, B., Croera, C., Savalli, N., Diodovich, C. & Gribaldo, L. (2004). Pancreas developing markers expressed on human mononucleated umbilical cord blood cells. Biochemical & Biophysical Research Communication 323, 315-322.
16. Eaves, C. & Lambie, H. (1995). Atlas of Human Hematopoietic Colonies, 75pp. Vancouver, Canada: StemCell Technologies, Inc.
17. Metcalf, D. (1977). In vitro cloning techniques for hemopoietic cells: Clinical applications. Annals of Internal Medicine 87, 483-488. (Pubitemid 8217096)
18. Rawlings, J.O., Pantula, S.G. & Dickey, D.A. (1998). Applied Regression Analysis: A Research Tool, 2nd edn, 658pp. New York, NY, USA: Springer-Verlag, Inc.
19. McCulloch, C.E. & Searle, S.R. (2001). Generalized, Linear, and Mixed Model, 325pp. New York, NY, USA: John Wiley & Sons.
20. Finney, D.J. (1964). Statistical Method in Biological Assay, 2nd edn, 551pp. New York, NY, USA: Hafner Publishing Co.
21. Fieller, E.C. (1940). The biological standardization of insulin. Journal of the Royal Statistical Society 7, 1-64.
22. Winer, B.J., Brown, D.R. & Michels, K.M. (1991). Statistical Principles in Experimental Design, 3rd edn, 1057pp. New York, NY, USA: McGraw-Hill, Inc.
23. SAS Institute, Inc. (1999). SAS OnlineDoc, Version 8. Cary, NC, USA: SAS Institute, Inc.
24. Archer, G., Balls, M., Bruner, L.H., Curren, R.D., Fentem, J.H., Holzhütter, H.G., Liebsch, M., Lovell, D.P. & Southee, J.A. (1997). The validation of toxicological prediction models. ATLA 25, 505-516.
25. Chabner, B.A. & Longo, D.L. (1996). Cancer Chemotherapy and Biotherapy, 2nd edn, 824pp. Wickford, RI, USA: Lippincott-Raven.
26. Dorr, R.T. & Von Hoff, D.D. (1994). Cancer Chemotherapy Handbook, 2nd edn, 1020pp. Norwalk, CT, USA: Appleton & Lange.
27. Anon. (2005). Safety data for 5-fluorouracil. Oxford, UK: Oxford University, Physical Chemistry Department. Available at: http://msds.chem.ox.ac. uk/FL/5-fluorouracil.html (Accessed 09.03.10).
28. Kratz, F., Ehling, G., Kauffmann, H.M. & Unger, C. (2007). Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin binding prodrug of the anticancer agent doxorubicin. Human & Experimental Toxicology 26, 19-35.
29. Anon. (2008). Information for Health Professionals: DBL® Etoposide Injection Data Sheet. Wellington, New Zealand: Medsafe, New Zealand Medicines and Medical Devices Safety Authority. Available at: http://www.medsafe.govt.nz/ profs/datasheet/e/etoposideinjmp.htm (Accessed 09.03.10).
30. Anon. (2000). Materials Safety Data Sheet: Fludarabine Phosphate for Injection, 8pp. Irvine, CA USA: Teva Parenteral Medicines, Inc. Available at: http://www.tevausa.com/assets/base/products/msds/Fludarabine-Lyo-MSDS.pdf (Accessed 09.03.10).
31. Anon. (2004). Safety data for methotrexate. Oxford, UK: Oxford University, Physical Chemistry Department. Available at: http://msds.chem.ox.ac. uk/ME/methotrexate.html (Accessed 09.03.10).
32. Kim, S.C., Kim, D.W., Shim, Y.H., Bang, J.S., Oh, H.S., Kim, S.W. & Seo, M.H. (2001). In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. Journal of Controlled Release 72, 194-202.